Nov 2022 Articles

Articles
Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing: A Cluster Randomized Clinical Trial
Adusumalli S, Kanter GP, Small DS, et al.
Journal:
JAMA Cardiol

First published: November 30, 2022 DOI: 10.1001/jamacardio.2022.4373
View
- Share
Articles
Knowledge of HbA1c and LDL-C treatment goals, subjective level of disease-related information and information needs in patients with atherosclerotic cardiovascular disease
Brockmeyer M, Wies E, Joerges J, et al.
Journal:
Clin Cardiol

First published: November 30, 2022 DOI: 10.1002/clc.23948
View
- Share
Articles
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
O’Donoghue ML, Rosenson RS, Gencer B, et al.
Journal:
N Engl J Med

First published: November 17, 2022 DOI: 10.1056/NEJMoa2211023
View
- Share
Articles
New Trends and Therapies for Familial Hypercholesterolemia
Alnouri F, Santos RD
Journal:
J Clin Med

First published: November 9, 2022 DOI: 10.3390/jcm11226638
View
- Share
Articles
Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project)
Sandhu AT, Rodriguez F, Ngo S, et al.
Journal:
Circulation

First published: November 7, 2022 DOI: 10.1161/CIRCULATIONAHA.122.062746
View
- Share
Articles
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan A, Glynn RJ, Fruchart JC, et al.
Journal:
NEJM

First published: November 5, 2022 DOI: 10.1056/NEJMoa2210645
View
- Share
Articles
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Ray KK, Kallend D, Leiter LA, et al.
Journal:
Eur Heart J

First published: November 4, 2022 DOI: 10.1093/eurheartj/ehac615
View
- Share
Articles
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
Ray KK, Raal FJ, Kallend DG, et al.
Journal:
Eur Heart J

First published: November 4, 2022 DOI: 10.1093/eurheartj/ehac594
View
- Share
Articles
Cardiovascular Risk Assessment and Management for Pediatricians
Schipper HS, de Ferranti S
Journal:
Pediatrics

First published: November 2, 2022 DOI: 10.1542/peds.2022-057957
View
- Share
Articles
Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease
Hedegaard BS, Bork CS, Kaltoft M, et al.
Journal:
J Am Coll Cardiol

First published: November 1, 2022 DOI: 10.1016/j.jacc.2022.09.021
View
- Share
Articles
HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity?
Ferdinand KC
Journal:
J Am Coll Cardiol

First published: November 1, 2022 DOI: 10.1016/j.jacc.2022.10.007
View
- Share
Articles
Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic
Chiou TT, Tomasi K, Taub PR, et al.
Journal:
J Clin Lipidol

First published: November 1, 2022 DOI: 10.1016/j.jacl.2022.10.009
View
- Share

1 2

Nov 2022 Articles

Articles

Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing: A Cluster Randomized Clinical Trial

Adusumalli S, Kanter GP, Small DS, et al.

Articles

Knowledge of HbA1c and LDL-C treatment goals, subjective level of disease-related information and information needs in patients with atherosclerotic cardiovascular disease

Brockmeyer M, Wies E, Joerges J, et al.

Articles

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

O’Donoghue ML, Rosenson RS, Gencer B, et al.

Articles

New Trends and Therapies for Familial Hypercholesterolemia

Alnouri F, Santos RD

Articles

Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project)

Sandhu AT, Rodriguez F, Ngo S, et al.

Articles

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Das Pradhan A, Glynn RJ, Fruchart JC, et al.

Articles

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Ray KK, Kallend D, Leiter LA, et al.

Articles

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Ray KK, Raal FJ, Kallend DG, et al.

Articles

Cardiovascular Risk Assessment and Management for Pediatricians

Schipper HS, de Ferranti S

Articles

Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease

Hedegaard BS, Bork CS, Kaltoft M, et al.

Articles

HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity?

Ferdinand KC

Articles

Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic

Chiou TT, Tomasi K, Taub PR, et al.

Articles

Effect of Nudges to Clinicians, Patients, or Both to Increase Statin Prescribing: A Cluster Randomized Clinical Trial

Adusumalli S, Kanter GP, Small DS, et al.

Share

Articles

Knowledge of HbA1c and LDL-C treatment goals, subjective level of disease-related information and information needs in patients with atherosclerotic cardiovascular disease

Brockmeyer M, Wies E, Joerges J, et al.

Share

Articles

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease

O’Donoghue ML, Rosenson RS, Gencer B, et al.

Share

Articles

New Trends and Therapies for Familial Hypercholesterolemia

Alnouri F, Santos RD

Share

Articles

Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project)

Sandhu AT, Rodriguez F, Ngo S, et al.

Share

Articles

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Das Pradhan A, Glynn RJ, Fruchart JC, et al.

Share

Articles

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Ray KK, Kallend D, Leiter LA, et al.

Share

Articles

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Ray KK, Raal FJ, Kallend DG, et al.

Share

Articles

Cardiovascular Risk Assessment and Management for Pediatricians

Schipper HS, de Ferranti S

Share

Articles

Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease

Hedegaard BS, Bork CS, Kaltoft M, et al.

Share

Articles

HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity?

Ferdinand KC

Share

Articles

Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic

Chiou TT, Tomasi K, Taub PR, et al.

Share